Servier, Oncodesign Select LRRK2 Inhibitor for Preclinical Studies

Servier, Oncodesign Select LRRK2 Inhibitor for Preclinical Studies

296922

Servier, Oncodesign Select LRRK2 Inhibitor for Preclinical Studies

Servier and Oncodesign have selected a LRRK2 inhibitor as their partnership program’s lead candidate for Parkinson’s disease and plan to start regulatory preclinical safety studies soon. A Phase 1 clinical trial is expected to begin in 2022. “We are particularly pleased with, and proud of, these results obtained in collaboration with Servier, a longstanding and major partner of our company since its creation and are confident in their ability to make the best use of this…

You must be logged in to read/download the full post.